{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:34:27Z","timestamp":1707525267293},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"DOI":"10.7759\/cureus.45687","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T13:22:02Z","timestamp":1695302522000},"source":"Crossref","is-referenced-by-count":0,"title":["Ras Association Domain Family 1A Gene Promoter Methylation as a Biomarker for Chronic Viral Hepatitis C-related Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"Abla A","family":"Abou Zeid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman T","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jylan K","family":"Ahdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa R","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnci.2013.05.003","article-title":"Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients","volume":"25","author":"Zeeneldin AA","year":"2013","unstructured":"Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst. 2013, 25:143-50. 10.1016\/j.jnci.2013.05.003","journal-title":"J Egypt Natl Canc Inst"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i12.1919","article-title":"Unique situation of hepatocellular carcinoma in Egypt: a review of epidemiology and control measures","volume":"13","author":"Ezzat R","year":"2021","unstructured":"Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: a review of epidemiology and control measures. World J Gastrointest Oncol. 2021, 13:1919-38. 10.4251\/wjgo.v13.i12.1919","journal-title":"World J Gastrointest Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach JK","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al.. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018, 67:358-80. 10.1002\/hep.29086","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","unstructured":"EASL Clinical Practice Guidelines. management of hepatocellular carcinoma. J Hepatol. 2018, 69:182-236. 10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.01.038","article-title":"Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma","volume":"342","author":"Pogribny IP","year":"2014","unstructured":"Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014, 342:223-30. 10.1016\/j.canlet.2012.01.038","journal-title":"Cancer Lett"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1804-1_37","article-title":"Detection of epigenetic aberrations in the development of hepatocellular carcinoma","volume":"1238","author":"Zhang Y","year":"2015","unstructured":"Zhang Y. Detection of epigenetic aberrations in the development of hepatocellular carcinoma. Methods Mol Biol. 2015, 1238:709-31. 10.1007\/978-1-4939-1804-1_37","journal-title":"Methods Mol Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications","volume":"45","author":"Delire B","year":"2015","unstructured":"Delire B, St\u00e4rkel P. The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest. 2015, 45:609-23. 10.1111\/eci.12441","journal-title":"Eur J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmu.2013.04.007","article-title":"Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients","volume":"2","author":"Kawasaki H","year":"2013","unstructured":"Kawasaki H, Kohosozawa R, Kobayashi M, Nishiko R, Abe H. Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients. Per Med Univ. 2013, 2:20-4. 10.1016\/j.pmu.2013.04.007","journal-title":"Per Med Univ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2012.06.009","article-title":"Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?","volume":"13","author":"Mohamed NA","year":"2012","unstructured":"Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?. Arab J Gastroenterol. 2012, 13:111-5. 10.1016\/j.ajg.2012.06.009","journal-title":"Arab J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig M","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al.. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022, 76:681-93. 10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.04.003","article-title":"Prognostic significance of RASSF1A promoter methylation in operable breast cancer","volume":"42","author":"Kioulafa M","year":"2009","unstructured":"Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem. 2009, 42:970-5. 10.1016\/j.clinbiochem.2009.04.003","journal-title":"Clin Biochem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmr021","article-title":"Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells","volume":"43","author":"Guo N","year":"2011","unstructured":"Guo N, Chen R, Li Z, et al.. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim Biophys Sin (Shanghai). 2011, 43:354-61. 10.1093\/abbs\/gmr021","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01084.x","article-title":"High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma","volume":"25","author":"Yeo W","year":"2005","unstructured":"Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005, 25:266-72. 10.1111\/j.1478-3231.2005.01084.x","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1198\/jasa.2007.s201","article-title":"Encyclopedia of statistical sciences","volume":"102","author":"Cavanaugh J","year":"2007","unstructured":"Cavanaugh J. Encyclopedia of statistical sciences. J Am Statistical Assoc. 2007, 102:1074-5.","journal-title":"J Am Statistical Assoc"},{"key":"ref16","article-title":"A Simple Guide to IBM SPSS Statistics for Version 20.0","author":"Kirkpatrick LA","year":"2013","unstructured":"Kirkpatrick LA, Feeney BC. A Simple Guide to IBM SPSS Statistics for Version 20.0. Wadsworth\/Cengage Learning, Australia; United Kingdom; 2013."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0317-x","article-title":"Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection","volume":"10","author":"Dong X","year":"2015","unstructured":"Dong X, He H, Zhang W, Yu D, Wang X, Chen Y. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection. Diagn Pathol. 2015, 10:133. 10.1186\/s13000-015-0317-x","journal-title":"Diagn Pathol"},{"key":"ref18","unstructured":"A language and environment for statistical\u00a0computing. (2013). Accessed. May 21, 2023: http:\/\/www.R-project.org\/."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal A","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011, 61:69-90. 10.3322\/caac.20107","journal-title":"CA Cancer J Clin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","unstructured":"EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol. 2012, 56:908-43. 10.1016\/j.jhep.2011.12.001","journal-title":"J Hepatol"},{"key":"ref21","article-title":"Blood Ras-association domain family 1 A gene methylation status in some liver diseases","volume":"8","author":"Azab NI","year":"2011","unstructured":"Azab NI, Abd El Kariem HM, Mowafi T, Fouad HF, El Abd AM. Blood Ras-association domain family 1 A gene methylation status in some liver diseases. Life Sci J. 2011, 8:531-9.","journal-title":"Life Sci J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/09674845.2019.1694123","article-title":"Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma","volume":"77","author":"El-Bendary M","year":"2020","unstructured":"El-Bendary M, Nour D, Arafa M, Neamatallah M. Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma. Br J Biomed Sci. 2020, 77:35-40. 10.1080\/09674845.2019.1694123","journal-title":"Br J Biomed Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9164-8","article-title":"Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma","volume":"4","author":"Hu L","year":"2010","unstructured":"Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 2010, 4:423-32. 10.1007\/s12072-010-9164-8","journal-title":"Hepatol Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2012.11.002","article-title":"Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma","volume":"5","author":"Zekri AR","year":"2014","unstructured":"Zekri AR, Bahnasy AA, Shoeab FE, et al.. Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res. 2014, 5:27-40. 10.1016\/j.jare.2012.11.002","journal-title":"J Adv Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153796","article-title":"RASSF1A and DOK1 promoter methylation levels in hepatocellular carcinoma, cirrhotic and non-cirrhotic liver, and correlation with liver cancer in Brazilian patients","volume":"11","author":"Ara\u00fajo OC","year":"2016","unstructured":"Ara\u00fajo OC, Rosa AS, Fernandes A, Niel C, Villela-Nogueira CA, Pannain V, Araujo NM. RASSF1A and DOK1 promoter methylation levels in hepatocellular carcinoma, cirrhotic and non-cirrhotic liver, and correlation with liver cancer in Brazilian patients. PLoS One. 2016, 11:e0153796. 10.1371\/journal.pone.0153796","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01638-5","article-title":"Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma","volume":"20","author":"Xu G","year":"2020","unstructured":"Xu G, Zhou X, Xing J, et al.. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell Int. 2020, 20:547. 10.1186\/s12935-020-01638-5","journal-title":"Cancer Cell Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2011.08.004","article-title":"Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma","volume":"91","author":"Huang ZH","year":"2011","unstructured":"Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011, 91:702-7. 10.1016\/j.yexmp.2011.08.004","journal-title":"Exp Mol Pathol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.07.070","article-title":"Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications","volume":"438","author":"Xu B","year":"2013","unstructured":"Xu B, Di J, Wang Z, Han X, Li Z, Luo X, Zheng Q. Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. Biochem Biophys Res Commun. 2013, 438:324-8. 10.1016\/j.bbrc.2013.07.070","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160623-ras-association-domain-family-1a-gene-promoter-methylation-as-a-biomarker-for-chronic-viral-hepatitis-c-related-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:27Z","timestamp":1707509307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160623-ras-association-domain-family-1a-gene-promoter-methylation-as-a-biomarker-for-chronic-viral-hepatitis-c-related-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.45687","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}